San Diego, CA USA (UroToday.com) Past studies have shown an association between chronic kidney disease (CKD) and cancer risk, as well as, higher cancer mortality in patients with bladder cancer. In order to further assess this association, Blute and colleagues evaluated whether moderate CKD is associated with higher rates of tumor recurrence and/or progression in patients with bladder cancer that have undergone transuretheral resection of bladder tumors (TURBT) for non-muscle invasive bladder cancer.
They created a multi-institutional database of patients treated at the University of Wisconsin and University of Rochester. Variables such as estimated glomerular filtration rate (eGFR) and association with recurrence-free survival and progression free survival were calculated and analyzed.
The authors reported a total 727 patients in this database. Of these patients, 55% had a recurrence, 19.9% had progression of tumor stage or grade, and 5.6% had progression to muscle invasive disease. According to eGFR calculations 183 patients had moderate to severe CKD. Of patients with an eGFR of greater than or equal to 60ml/min, the 5 year recurrence free survival rate was 46% and the 5-year progression free survival rate was 83%. However, of patients with an eGFR of less than or equal to 60ml/min, the 5 year recurrence free survival rate was 27%, the 5-year progression free survival rate was 71%, and were associated with progression to muscle invasive disease.
Their analysis of the database revealed that moderate CKD at first transuretheral resection is associated with reduced recurrence-free survival and progression free survival. The authors concluded from their findings that these patients should be considered high risk and be provided increased surveillance after bladder cancer diagnosis.
Presented By: Michael L. Blute Jr, MD
Written By: by Renai Yoon; Research Associate, Department of Urology, University of California, Irvine at the 2016 AUA Annual Meeting - May 6 - 10, 2016 – San Diego, California, USA